{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:36:39Z","timestamp":1793370999904,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bulcan.2026.07.016","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:16:02Z","timestamp":1790136962000},"page":"1183-1191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T in vivo\u00a0: quand le patient devient sa propre usine de production"],"prefix":"10.1016","volume":"113","author":[{"given":"Fran\u00e7ois","family":"Vilcot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole-Anne","family":"Brug\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Fuentealba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.07.016_bib0250","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0255","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0260","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jama.2025.21721","article-title":"T-cell therapy: evidence-based trial design for chimeric antigen receptor t-cell therapy in oncology","volume":"335","author":"Mahat","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0270","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19\u00a0CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2\u00a0CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0275","doi-asserted-by":"crossref","first-page":"200980","DOI":"10.1016\/j.omton.2025.200980","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0280","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501\u00a0in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0285","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa2505478","article-title":"Universal base-edited CAR7T cells for T-cell acute lymphoblastic leukemia","volume":"394","author":"Chiesa","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0290","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/bloodadvances.2024015013","article-title":"Receiving CAR T-cells gets faster, but not for all in need","volume":"9","author":"Ramos","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0295","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41588-025-02234-x","article-title":"The long-term effects of chemotherapy on normal blood cells","volume":"57","author":"Mitchell","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0300","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1\u00a0study","volume":"32","author":"An","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0305","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19\u00a0CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0310","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0315","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-252","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0320","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR T\u00a0cell therapy in the DESCAR-T registry","volume":"31","author":"Dulery","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0325","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0330","doi-asserted-by":"crossref","first-page":"105834","DOI":"10.1016\/j.ebiom.2025.105834","article-title":"Viral and non-viral vectors in gene therapy: current state and clinical perspectives","volume":"118","author":"Geng","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0335","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/v17060802","article-title":"Progress in pseudotyping lentiviral vectors towards cell-specific gene delivery in vivo","volume":"17","author":"Arduini","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0340","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0345","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2\u00a0promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0350","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0355","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0360","doi-asserted-by":"crossref","first-page":"e011759","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0365","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41467-024-49508-2","article-title":"Optimizing 5\u2032UTRs for mRNA-delivered gene editing using deep learning","volume":"15","author":"Castillo-Hair","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0370","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0375","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41392-025-02512-4","article-title":"Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy","volume":"10","author":"Hu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0380","doi-asserted-by":"crossref","first-page":"1501365","DOI":"10.3389\/fimmu.2024.1501365","article-title":"In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models","volume":"15","author":"Argueta","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0450","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.trechm.2025.09.011","article-title":"Smart lipid nanoparticles: the chemistry driving targeted therapeutics","volume":"7","author":"Abbrederis","year":"2025","journal-title":"Trends Chem"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0455","doi-asserted-by":"crossref","first-page":"e006292","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0390","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol Ther"},{"issue":"suppl 3","key":"10.1016\/j.bulcan.2026.07.016_bib0385","first-page":"1482","article-title":"In-vivo CAR-T cells produced by specific virus in refractory B cell lymphoma","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0395","article-title":"Interius BioTherapeutics Inc. Safety of INT2104 in participants aged 18 years and older who have b-cell cancer that came back after prior treatment","year":"2025","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0400","article-title":"A phase 1 study of UB-VV111 with and without rapamycin in relapsed\/refractory CD19+ B-cell malignancies","year":"2025","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0405","article-title":"The CD19\/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed\/Refractory B-cell Malignancies","author":"Fan","year":"2025","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0415","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood-2025-103","article-title":"Precision in vivo CAR-T generation via CLAMP-enabled mRNA delivery: toward scalable and translatable cell therapy","volume":"146","author":"Sun","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0420","article-title":"One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r\/r B-NHL","author":"Hu","year":"2025","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0425","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/blood-2025-4117","article-title":"In Vivo pan CAR therapy utilizing circular RNA for treatment of multiple myeloma","volume":"146","author":"Silver","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0430","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood-2025-104","article-title":"In Vivo pan CAR therapy utilizing circular RNA for treatment of autoimmune diseases","volume":"146","author":"Soto","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0435","unstructured":"CREATE Medicines. CREATE Medicines and Amsterdam University Medical Center Initiate First In Vivo CAR Therapy Trial in Frontline Setting for Solid Tumors n.d. https:\/\/www.prnewswire.com\/news-releases\/create-medicines-and-amsterdam-university-medical-center-initiate-first-in-vivo-car-therapy-trial-in-frontline-setting-for-solid-tumors-302596696.html (accessed December 12, 2025)."},{"issue":"Suppl 2","key":"10.1016\/j.bulcan.2026.07.016_bib0440","first-page":"1125","article-title":"Preclinical development of MT-303, a novel LNP-formulated GPC3-specific CAR mRNA, for in vivo programming of monocytes to treat hepatocellular carcinoma","volume":"12","author":"Argueta","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0445","unstructured":"CREATE Medicines. Myeloid Therapeutics Rebrands as CREATE Medicines, Focused on Transforming Immunotherapy Through RNA-Based In Vivo Multi-Immune Programming n.d. https:\/\/www.prnewswire.com\/news-releases\/myeloid-therapeutics-rebrands-as-create-medicines-focused-on-transforming-immunotherapy-through-rna-based-in-vivo-multi-immune-programming-302575510.html (accessed December 11, 2025)."},{"key":"10.1016\/j.bulcan.2026.07.016_bib0460","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a novel anti-CD19\u00a0chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions","volume":"12","author":"Castella","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0465","unstructured":"CREATE Medicines Announces Positive First-in-Human Results for MT-302\u00a0n.d. https:\/\/www.prnewswire.com\/news-releases\/create-medicines-announces-positive-first-in-human-results-for-mt-302-302608674.html (accessed March 29, 2026)."},{"key":"10.1016\/j.bulcan.2026.07.016_bib0470","doi-asserted-by":"crossref","first-page":"e011759","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0475","doi-asserted-by":"crossref","first-page":"e2310078","DOI":"10.1002\/adma.202310078","article-title":"Injectable supramolecular hydrogels for in situ programming of Car-T cells toward solid tumor immunotherapy","volume":"36","author":"Zhu","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0480","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","article-title":"Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells","volume":"40","author":"Agarwalla","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0485","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-026-10235-x","article-title":"In vivo site-specific engineering to reprogram T cells","volume":"652","author":"Nyberg","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2026.07.016_bib0245","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:26:06Z","timestamp":1793370366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0007455126003966"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.016","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T in vivo\u00a0: quand le patient devient sa propre usine de production","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}